Drug intelligence / Profile preview

MSM-605

Development stage: Preclinical
Lead developer: MSM Medical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MSM-605 is a monoclonal antibody developed by MSM Medical, currently in preclinical development for the treatment of Respiratory Syncytial Virus (RSV) infection, Chronic Obstructive Pulmonary Disease (COPD), and asthma. The antibody targets an undisclosed membrane protein or G protein-coupled receptor (GPCR). According to the company's pipeline, the program is in the preclinical stage for RSV and in the lead optimization phase for COPD and asthma.

Beyond the preview

Go deeper on MSM-605.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSM-605.

Explore the full profile